Leading infectious diseases problems in Turkey

Clinical Microbiology and Infection

Volumn 18, Issue 11, 2012, Pages 1056-1067

  Erdem, H ^a   Akova, M ^b  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antimicrobial resistance; Infectious diseases; Turkey

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CAPREOMYCIN; CEFACLOR; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ACINETOBACTER; ANIMAL HUSBANDRY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CONTAMINATION; BORRELIA BURGDORFERI; BRUCELLA ABORTUS; BRUCELLA MELITENSIS; BRUCELLOSIS; CLINICAL FEATURE; CRIMEAN CONGO HEMORRHAGIC FEVER; DELTA AGENT HEPATITIS; ELECTRONIC MEDICAL RECORD; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FLAVIVIRUS INFECTION; FRANCISELLA TULARENSIS; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HANTAVIRUS INFECTION; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; LYME DISEASE; MALARIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NAIRO VIRUS; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PNEUMOCOCCAL INFECTION; POSTTRANSFUSION HEPATITIS; PRIORITY JOURNAL; PROSTITUTION; PSEUDOMONAS AERUGINOSA; REVIEW; RICKETTSIA CONORII; RICKETTSIOSIS; SEROEPIDEMIOLOGY; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE; STAPHYLOCOCCUS AUREUS; TERTIARY HEALTH CARE; TUBERCULOSIS; TULAREMIA; TURKEY (REPUBLIC); URINARY TRACT INFECTION; VIRUS TRANSMISSION; WATER CONTAMINATION; WEST NILE FLAVIVIRUS;

NEGIBACTERIA; POSIBACTERIA;

EID: 84867727464     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12000     Document Type: Review

References (206)

1. Bruselloz (brucellosis), monthly epidemiology report. RHSM publications. 2004, 89-96.
2. Irmak H. Brusellozun kontrolü amaciyla saglik bakanliginca yapilan calişmalar [The activities of the ministry of health for the control of brucellosis]. 3. Türkiye Zoonotik Hastaliklar Simpozyumu Kitabi (3rd Turkey zoonotic diseases symposium book). Ankara:, 2010; 254-258.
3. Yuce A, Alp-Cavus S. Türkiye'de bruselloz: Genel bakis [Brucellosis in Turkey: an overview]. Klimik Derg 2006; 19: 87-97.
4. Yumuk Z, O'Callaghan D. Brucellosis in Turkey-an overview. Int J Infect Dis 2012; 16: e228-e235.
5. Ciftdogan DY, Bayram N, Vardar F. Brucellosis as a cause of fever of unknown origin in children admitted to a tertiary hospital in the Aegean region of Turkey. Vector Borne Zoonotic Dis 2011; 11: 1037-1040.
6. Citak EC, Arman D. Brucella melitensis: a rare cause of febrile neutropenia. Pediatr Hematol Oncol 2011; 28: 83-85.
7. Ozbalci D, Ergene U, Cetin CB. Brucellosis: a rare cause of febrile neutropenia in acute myeloblastic leukemia. Med Oncol 2011; 28: 255-257.
8. Sari I, Altuntas F, Hacioglu S et al. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis. Am J Hematol 2008; 83: 334-339.
9. Metan G, Sardan YC, Hascelik G. Brucellosis in all patients with febrile neutropenia. Leuk Lymphoma 2006; 47: 954-956.
10. Sayin-Kutlu S, Kutlu M, Ergonul O et al. Laboratory-acquired brucellosis in Turkey. J Hosp Infect 2012; 80: 326-330.
11. Erdem H, Ulu-Kilic A, Kilic S et al. Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study. Antimicrob Agents Chemother 2012; 56: 1523-1528.
12. Buzgan T, Karahocagil MK, Irmak H et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 2010; 14: e469-e478.
13. Calik S, Gokengin D. Human brucellosis in Turkey: a review of the literature between 1990 and 2009. Turk J Med Sci 2011; 41: 549-555.
14. Koruk ST, Erdem H, Koruk I et al. Management of brucella endocarditis: results of the Gulhane study. Int J Antimicrob Agents 2012; 40: 145-150.
15. Akalin HE, Unal S, Gur D, Baykal M. Ofloxacin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1990; 326-328.
16. Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831-1834.
17. Kocagoz S, Akova M, Altun B, Gur D, Hascelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect 2002; 8: 240-242.
18. Golem SB. Luleburgaz'da yeni bir tularemi epidemisi [A recent tularemia outbreak in Luleburgaz]. Turk Hyg Exp Biol Bull 1945; 5: 28-40.
19. Kilic S. A general overview of Francisella tularensis and the epidemiology of tularemia in Turkey. Flora Derg 2010; 15: 37-58.
20. Celebi G, Baruonu F, Ayoglu F et al. Tularemia, a reemerging disease in northwest Turkey: epidemiological investigation and evaluation of treatment responses. Jpn J Infect Dis 2006; 59: 229-234.
21. Gurcan S, Otkun MT, Otkun M, Arikan OK, Ozer B. An outbreak of tularemia in western Black Sea region of Turkey. Yonsei Med J 2004; 45: 17-22.
22. Yazgi H, Uyanik MH, Ertek M et al. Tularemia seroprevalence in the risky population living in both rural and urban areas of Erzurum. Mikrobiyol Bul 2011; 45: 67-74.
23. Gurcan S, Karabay O, Karadenizli A, Karagol C, Kantardjiev T, Ivanov IN. Characteristics of the Turkish isolates of Francisella tularensis. Jpn J Infect Dis 2008; 61: 223-225.
24. Ulu Kilic A, Kilic S, Sencan I et al. A water-borne tularemia outbreak caused by Francisella tularensis subspecies holarctica in central Anatolia region. Mikrobiyol Bul 2011; 45: 234-247.
25. Ozdemir D, Sencan I, Annakkaya AN et al. Comparison of the 2000 and 2005 outbreaks of tularemia in the Duzce region of Turkey. Jpn J Infect Dis 2007; 60: 51-52.
26. Leblebicioglu H, Esen S, Turan D et al. Outbreak of tularemia: a case-control study and environmental investigation in Turkey. Int J Infect Dis 2008; 12: 265-269.
27. Yesilyurt M, Kilic S, Celebi B et al. Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the central Anatolia region of Turkey. J Antimicrob Chemother 2011; 66: 2588-2592.
28. Ciftci F, Tozkoparan E, Deniz O, Bozkanat E, Kibaroglu E, Demirci N. The incidence of tuberculosis in the armed forces: a good reflection of the whole population. Int J Tuberc Lung Dis 2004; 8: 965-968.
29. Tabak F, Mert A, Celik AD et al. Fever of unknown origin in Turkey. Infection 2003; 31: 417-420.
30. Kucukardali Y, Oncul O, Cavuslu S et al. The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. Int J Infect Dis 2008; 12: 71-79.
31. Saltoglu N, Tasova Y, Midikli D, Aksu HS, Sanli A, Dundar IH. Fever of unknown origin in Turkey: evaluation of 87 cases during a nine-year-period of study. J Infect 2004; 48: 81-85.
32. Baylan O. Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease. Mikrobiyol Bul 2011; 45: 181-195.
33. Tahaoglu K, Kizkin O, Karagoz T, Tor M, Partal M, Sadoglu T. High initial and acquired drug resistance in pulmonary tuberculosis in Turkey. Tuber Lung Dis 1994; 75: 324-328.
34. Kartaloglu Z, Bozkanat E, Ozturkeri H, Okutan O, Ilvan A. Primary antituberculosis drug resistance at Turkish military chest diseases hospital in Istanbul. Med Princ Pract 2002; 11: 202-205.
35. Kilicaslan Z, Albal H, Kiyan E, Aydemir N, Seber E. Drug resistance in pulmonary tuberculosis in Istanbul. Eur J Clin Microbiol Infect Dis 2002; 21: 763-764.
36. Durmaz R, Ozerol IH, Durmaz B, Gunal S, Senoglu A, Evliyaoglu E. Primary drug resistance and molecular epidemiology of Mycobacterium tuberculosis isolates from patients in a population with high tuberculosis incidence in Turkey. Microb Drug Resist 2003; 9: 361-366.
37. Anonymous. Report on fight against tuberculosis in Turkey. 24 March 2009. Ankara: Department of Fight Against Tuberculosis, Turkish Republic of Ministry of Health.
38. Ozkutuk N, Surucuoglu S, Gazi H, Coskun M, Ozkutuk A, Ozbakkaloglu B. Second-line drug susceptibilities of multidrug-resistant Mycobacterium tuberculosis isolates in Aegean region-Turkey. Turk J Med Sci 2008; 38: 245-250.
39. Kayali R, Coplu N, Ceyhan I, Ocak F, Citil BE, Esen B. The rates of resistance to second-line drugs in multidrug resistant Mycobacterium tuberculosis strains. Mikrobiyol Bul 2006; 40: 1-7.
40. Eroglu C, Esen S, Hokelek M et al. Menenjit ve ensefalit bulgulari ile karakterize bir lyme menenjiti olgusu [A case of lyme meningitis characterized with meningitis and encephalitis findings]. Infeks Derg 2002; 16: 225-228.
41. Polat E, Turhan V, Aslan M, Musellim B, Onem Y, Ertugrul B. First report of three culture confirmed human lyme cases in Turkey. Mikrobiyol Bul 2010; 44: 133-139.
42. Koc F, Bozdemir H, Pekoz T, Aksu HS, Ozcan S, Kurdak H. Lyme disease presenting as subacute transverse myelitis. Acta Neurol Belg 2009; 109: 326-329.
43. Bulut C, Tufan ZK, Altun S, Altinel E, Kinikli S, Demiroz AP. An overlooked disease of tick bites: Lyme disease. Mikrobiyol Bul 2009; 43: 487-492.
44. Demirci M, Yorgancigil B, Tahan V, Arda M. Isparta yöresinde kene isirigi oykusu olanlarda lyme hastaligi seropozitifligi [The lyme disease seropositivity in Isparta province in those with a history of tick-bite]. Infeks Derg 2001; 15: 17-20.
45. Sen E, Uchishima Y, Okamoto Y et al. Molecular detection of Anaplasma phagocytophilum and Borrelia burgdorferi in Ixodes ricinus ticks from Istanbul metropolitan area and rural Trakya (Thrace) region of north-western Turkey. Ticks Tick Borne Dis 2011; 2: 94-98.
46. Erdem H, Tetik A, Arun O, Besirbellioglu BA, Coskun O, Eyigun CP. War and infection in the pre-antibiotic era: the third Ottoman army in 1915. Scand J Infect Dis 2011; 43: 690-695.
47. Karatepe M. The role of Turkish physicians in the vaccination against typhus during the years of World War I. Mikrobiyol Bul 2008; 42: 301-313.
48. Payzin S, Akan E. Residual agglutinins against rickettsial agents in human sera from central and eastern Turkey and their relation to cardiovascular diseases. Bull World Health Organ 1966; 35: 111-117.
49. Raoult D. Introduction to rickettsioses, ehrlichioses, and anaplasmosis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone, 2010; 2495-2499.
50. Badiaga S, Brouqui P. Human louse-transmitted infectious diseases. Clin Microbiol Infect 2012; 18: 332-337.
51. Kuloglu F, Rolain JM, Fournier PE, Akata F, Tugrul M, Raoult D. First isolation of Rickettsia conorii from humans in the Trakya (European) region of Turkey. Eur J Clin Microbiol Infect Dis 2004; 23: 609-614.
52. Mert A, Ozaras R, Tabak F, Bilir M, Ozturk R. Mediterranean spotted fever: a review of fifteen cases. J Dermatol 2006; 33: 103-107.
53. Kuloglu F, Rolain JM, Celik AD, Akata F, Tugrul M, Raoult D. Prospective evaluation of rickettsioses in the Trakya (European) region of Turkey in 2005. Clin Microbiol Infect 2009; 15 (suppl 2): 220-221.
54. Oztoprak N, Celebi G, Aydemir H et al. Mediterranean spotted fever due to contact with dog-tick. Mikrobiyol Bul 2008; 42: 701-706.
55. Ozkan A, Ozkalemkas F, Ali R et al. Mediterranean spotted fever: presentation with pancytopenia. Am J Hematol 2006; 81: 646-647.
56. Erbay A, Kayaaslan B, Akinci E et al. HIv/AIDS olgularinin epidemiyolojik, klinik ve laboratuvar özelliklerinin degerlendirilmesi [Evaluation of epidemiological, clinical and laboratory features of HIV/AIDS cases]. Flora Derg 2009; 14: 36-42.
57. Afsar I, Gungor S, Sener AG, Yurtsever SG. The prevalence of HBV, HCV and HIV infections among blood donors in Izmir, Turkey. Indian J Med Microbiol 2008; 26: 288-289.
58. Coskun O, Gul C, Erdem H, Bedir O, Eyigun CP. Prevalence of HIV and syphilis among Turkish blood donors. Ann Saudi Med 2008; 28: 470.
59. Guzelant A, Kurtoglu MG, Kaya M, Kesli R, Baysal B. Kan vericilerinde ve bir aǧi{dotless}z-diş saǧliǧi merkezi çalişanlarinda Hepatit B, Hepatit C ve HIV seroprevalansi ile vericilerde risk faktörlerinin arastirilmasi [The seroprevalence of Hepatitis B, Hepatitis C and HIV in blood donors and workers in a dentistry center and risk factors for infection in blood donors]. Infeks Derg 2008; 22: 189-195.
60. Stanojevic M, Alexiev I, Beshkov D et al. HIV-1 molecular epidemiology in the Balkans-a melting pot for high genetic diversity. AIDS Rev 2012; 14: 28-36.
61. Tumer A. Dünyada ve Türkiye'de güncel verilerle HIV/AIDS [HIV/AIDS in Turkey and in the world according to current data]. Turk HIV/AIDS Derg 2006; 9: 99-103.
62. Hariri AG, Karadag F, Gokalp P, Essizoglu A. Risky sexual behavior among patients in Turkey with bipolar disorder, schizophrenia, and heroin addiction. J Sex Med 2011; 8: 2284-2291.
63. Avcikurt C, Koroglu O, Koroglu A, Avcikurt AS. HIV/AIDS awareness and attitudes of tour guides in Turkey. Cult Health Sex 2011; 13: 233-243.
64. Celikbas A, Ergonul O, Baykam N et al. Epidemiologic and clinical characteristics of HIV/AIDS patients in Turkey, where the prevalence is the lowest in the region. J Int Assoc Physicians AIDS Care (Chic) 2008; 7: 42-45.
65. Ergonul O. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012; 2: 215-220.
66. Chumakov MP. A new tick-borne virus disease-Crimean hemorrhagic fever. In: Sokolov AA, Chumakov MP, Kolachev AA, eds. Crimean hemorrhagic fever (acute infectious capillary toxicosis). Moscow: Izd Otd Primorskoi Armii, 1945; 13-45.
67. Simpson DI, Knight EM, Courtois G, Williams MC, Weinbren MP, Kibukamusoke JW. Congo virus: a hitherto undescribed virus occurring in Africa. I. Human isolations-clinical notes. East Afr Med J 1967; 44: 86-92.
68. Vorou RM. Crimean-Congo hemorrhagic fever in southeastern europe. Int J Infect Dis 2009; 13: 659-662.
69. Papa A, Dalla V, Papadimitriou E, Kartalis GN, Antoniadis A. Emergence of Crimean-Congo haemorrhagic fever in Greece. Clin Microbiol Infect 2010; 16: 843-847.
70. Tantawi HH, Al-Moslih MI, Al-Janabi NY et al. Crimean-Congo haemorrhagic fever virus in Iraq: isolation, identification and electron microscopy. Acta Virol 1980; 24: 464-467.
71. Chinikar S, Ghiasi SM, Moradi M et al. Geographical distribution and surveillance of Crimean-Congo hemorrhagic fever in Iran. Vector Borne Zoonotic Dis 2010; 10: 705-708.
72. Gozalan A, Akin L, Rolain JM et al. Epidemiological evaluation of a possible outbreak in and nearby Tokat province. Mikrobiyol Bul 2004; 38: 33-44.
73. Karti SS, Odabasi Z, Korten V et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004; 10: 1379-1384.
74. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H. Crimean-Congo haemorrhagic fever outbreak in middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005; 54: 385-389.
75. Kader C, Erbay A, Aker S, Alper S. Kastamonu ili aile hekimlerinin Ki{dotless}ri{dotless}m-Kongo kanamali{dotless} atesi konusunda bilgi düzeylerinin degerlendirilmesi [Evaluation of the knowledge of family physicians regarding Crimean-Congo haemorrhagic fever in Kastamonu]. Flora Derg 2011; 16: 61-66.
76. Maltezou HC, Andonova L, Andraghetti R et al. Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. Euro Surveill 2010; 15: 19504.
77. Elaldi N. Ki{dotless}ri{dotless}m-Kongo kanamali{dotless} atesi'nin kan merkezi is yüküne etkisi [The effect of Crimean-Congo hemorrhagic fever on blood transfusion center workload]. Cumhuriyet Ti{dotless}p Derg 2010; 32: 292-297.
78. Hekimoglu O, Ozer N, Ergunay K, Ozkul A. Species distribution and detection of Crimean Congo hemorrhagic fever virus (CCHFV) in field-collected ticks in Ankara province, central Anatolia, Turkey. Exp Appl Acarol 2012; 56: 75-84.
79. Koksal I, Yilmaz G, Iskender S et al. The first Crimean-Congo hemorrhagic fever case in the winter season from Turkey. Intervirology 2011; 54: 144-145.
80. Aksoy HZ, Yilmaz G, Aksoy F, Koksal I. Crimean-Congo haemorrhagic fever presenting as epididymo-orchitis. J Clin Virol 2010; 48: 282-284.
81. Yilmaz G, Koksal I, Topbas M, Yilmaz H, Aksoy F. The effectiveness of routine laboratory findings in determining disease severity in patients with Crimean-Congo hemorrhagic fever: severity prediction criteria. J Clin Virol 2010; 47: 361-365.
82. Kaya S, Yilmaz G, Ertunc B, Koksal I. Parotitis associated with Crimean Congo hemorrhagic fever virus. J Clin Virol 2012; 53: 159-161.
83. Engin A, Erdogan H, Ozec AV et al. Ocular findings in patients with Crimean-Congo hemorrhagic fever. Am J Ophthalmol 2009; 147: 634-638.
84. Engin A, Yilmaz MB, Elaldi N et al. Crimean-Congo hemorrhagic fever: does it involve the heart? Int J Infect Dis 2009; 13: 369-373.
85. Celikbas A, Ergonul O, Dokuzoguz B, Eren S, Baykam N, Polat-Duzgun A. Crimean Congo hemorrhagic fever infection simulating acute appendicitis. J Infect 2005; 50: 363-365.
86. Ergonul O, Celikbas A, Yildirim U et al. Pregnancy and Crimean-Congo haemorrhagic fever. Clin Microbiol Infect 2010; 16: 647-650.
87. Appannanavar SB, Mishra B. An update on Crimean Congo hemorrhagic fever. J Glob Infect Dis 2011; 3: 285-292.
88. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39: 284-287.
89. Bodur H, Akinci E, Ascioglu S, Onguru P, Uyar Y. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg Infect Dis 2012; 18: 640-642.
90. Ergonul O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006; 6: 203-214.
91. Ergonul O. Debate (see Elaldi N et al., efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. Journal of Infection 2009; 58: 238-244). Biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever. J Infect 2009; 59: 284-286. Author reply 286-289.
92. Elaldi N, Bodur H, Ascioglu S et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect 2009; 58: 238-244.
93. Ozkurt Z, Kiki I, Erol S et al. Crimean-Congo hemorrhagic fever in eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006; 52: 207-215.
94. Cevik MA, Elaldi N, Akinci E et al. A preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean-Congo hemorrhagic fever. J Infect 2008; 57: 350-351.
95. Heyman P, Ceianu CS, Christova I et al. A five-year perspective on the situation of haemorrhagic fever with renal syndrome and status of the hantavirus reservoirs in Europe, 2005-2010. Euro Surveill 2011; 16: 19961.
96. Lednicky JA. Hantaviruses. A short review. Arch Pathol Lab Med 2003; 127: 30-35.
97. Bi Z, Formenty PB, Roth CE. Hantavirus infection: a review and global update. J Infect Dev Ctries 2008; 2: 3-23.
98. Ertek M, Buzgan T. An outbreak caused by hantavirus in the Black Sea region of Turkey, January-May 2009. Euro Surveill 2009; 14: 19214.
99. Kaya S, Yilmaz G, Erensoy S, Yagci Caglayik D, Uyar Y, Koksal I. Hantavirus infection: two case reports from a province in the eastern Black Sea region, Turkey. Mikrobiyol Bul 2010; 44: 479-487.
100. Sariguzel N, Hofmann J, Canpolat AT et al. Dobrava hantavirus infection complicated by panhypopituitarism, Istanbul, Turkey, 2010. Emerg Infect Dis 2012; 18: 1180-1183.
101. Oncul O, Atalay Y, Onem Y et al. Hantavirus infection in Istanbul, Turkey. Emerg Infect Dis 2011; 17: 303-304.
102. Sari{dotless} T, Temuçin F, Kaçar M, Oral B, Tülek N. Renal sendromla seyreden hantavirus enfeksiyonu; olgu sunumu [A hantavirus infection with renal syndrome: case presentation]. In: Klimik Congress Book. Antalya, 322, 2011; 18-13. Please reformat this reference in journal style, and query author for editors, publisher, the meaning of '322', and the meaning of '18-13'.In: Klimik Congress Book. Antalya, 322, 2011; 18-13..
103. Laakkonen J, Kallio-Kokko H, Oktem MA et al. Serological survey for viral pathogens in Turkish rodents. J Wildl Dis 2006; 42: 672-676.
104. Gubler DJ. The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis 2007; 45: 1039-1046.
105. Meco O. West Nile arbovirus antibodies with hemagglutination inhibition (HI) in residents of southeast Anatolia. Mikrobiyol Bul 1977; 11: 3-17.
106. Ergunay K, Ozkul A. Confirmation of West Nile virus seroreactivity in central nervous system infections of unknown etiology from Ankara province, central anatolia, Turkey. Mikrobiyol Bul 2011; 45: 381-383.
107. Tapisiz A, Emiralioglu N, Vural O et al. The first report of West Nile virus infection in a child from Turkey. Turk J Pediatr 2011; 53: 317-319.
108. Arpaci F, Cetin T, Kubar A. West Nile virus infection in a patient with acute graft-versus-host disease. Haematologica 2009; 94: 687.
109. Kocak-Tufan Z, Bulut C. Bati{dotless} Nil virüsü Infeksiyonlari{dotless} [West Nile virus infections]. Flora Derg 2011; 16: 1-9.
110. Kalaycioglu H, Korukluoglu G, Ozkul A et al. Emergence of West Nile virus infections in humans in Turkey, 2010 to 2011. Euro Surveill 2012; 17: 20182.
111. Hizel K, Yenicesu I, Erdal B et al. Investigation of West Nile virus seroprevalence in healthy blood donors. Mikrobiyol Bul 2010; 44: 425-430.
112. Ayturan S, Aydogan S, Ergunay K, Ozcebe OI, Us D. Investigation of West Nile virus seroprevalence in Hacettepe University hospital blood donors and confirmation of the positive results by plaque reduction neutralization test. Mikrobiyol Bul 2011; 45: 113-124.
113. Ozer N, Ergunay K, Simsek F et al. West Nile virus studies in the Sanliurfa province of Turkey. J Vector Ecol 2007; 32: 202-206.
114. Toy M, Onder FO, Wormann T et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis 2011; 11: 337.
115. Tunc N, Eraydin H, Cetinkaya E, Oduncu MK, Toy S. Siirt Devlet Hastanesi'ne başvuran hastalarda HbsAg, anti-Hbs, anti-HCV ve anti-HIV seroprevalansi{dotless} [HbsAg, anti-Hbs, anti-HCV and anti-HIV seroprevalence of the patients admitted to Siirt Public Hospital]. Viral Hepatit Derg 2011; 17: 7-11.
116. Demiraslan H, Aksoz S. Adi{dotless}yaman ili kan vericilerindeki HbsAg ve anti-HCV si{dotless}kli{dotless}ǧi{dotless}ni{dotless}n deǧerlendirilmesi [The evaluation of HbsAg and anti-HCV seroprevalences of blood donors in Adiyaman]. Viral Hepatit Derg 2008; 13: 23-26.
117. Kose S, Ece G, Gozaydin A, Ergin O. İzmir Sosyal Hizmetler ve Cocuk Esirgeme Kurumuna baǧli{dotless} yetiştirme yurtlari{dotless}nda yaşayan çocuklarda Hepatit B ve Hepatit C seroprevalansi{dotless} [Seroprevalence of hepatitis B and hepatitis C in children living in Izmir Social Services and Child Protection Institution]. Viral Hepatit Derg 2010; 16: 64-68.
118. Altuntas-Aydin O, Kumbasar-Karaosmanoglu H, Kokrek A, Isik ME, Nazlican Ö. İstanbul bölgesi kan donörlerinde HbsAg, anti-HCV ve anti-HIV seroprevalansi{dotless} [Seroprevalences of HbsAg, anti-HCV and anti-HIV among blood donors in Istanbul]. Viral Hepatit Derg 2009; 14: 69-73.
119. Oksuz S, Yildirim M, Ozaydin C, Sahin I, Sencan I. Düzce bölgesi kan vericilerinde HbsAg, anti-HCV ve anti-HIV seroprevalansi{dotless} [Seropositivity rates of HbsAg, anti-HCV and anti-HIV in blood donors in Düzce area]. Viral Hepatit Derg 2008; 13: 27-30.
120. Sahin D, Sahin I, Sozer F, Onder F. Ki{dotless}rklareli Devlet Hastanesi kan merkezine başvuran donörlerde HBV, HCV ve HIV seroprevalansi{dotless}: Retrospektif bir calisma [HBV, HCV and HIV seroprevalance in applicant donors of Kirklareli State Hospital blood center: a retrospective study]. Viral Hepatit Derg 2008; 13: 31-35.
121. Kumbasar Karaosmanoglu H, Altuntas Aydin O, Sandikci S, Yamanlar ER, Nazlican O. Seroprevalence of hepatitis B: do blood donors represent the general population? J Infect Dev Ctries 2012; 6: 181-183.
122. Atalay MA, Gokahmetoglu S, Aygen B. Genotypes of hepatitis B virus in central Anatolia, Kayseri, Turkey. Saudi Med J 2011; 32: 360-363.
123. Kulah C, Cirak MY. Determination of hepatitis B virus genotypes by DNA sequence analysis in patients from Ankara, Turkey. Mikrobiyol Bul 2010; 44: 245-253.
124. Tosun S, Deveci S, Kaplan Y, Kasirga E. Should a booster dose be administered in children after mass immunization for hepatitis B? Hepat Mon 2011; 11: 440-444.
125. Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for Delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008; 28: 494-498.
126. Abbas Z, Jafri W, Raza S. Hepatitis D: scenario in the Asia-Pacific region. World J Gastroenterol 2010; 16: 554-562.
127. Demirdal T, Demirturk N, Asci Z. Afyonkarahisar ilinde Hepatit Delta virusu seroprevalansi{dotless} [Seroprevalence of hepatitis delta virus in Afyonkarahisar]. Viral Hepatit Derg 2009; 14: 104-107.
128. Turkdogan MK, Bozkurt H, Uygan I et al. Chronic hepatitis delta virus infection in Van region of eastern Turkey. Turk J Gastroenterol 2005; 16: 17-20.
129. Izmirli S, Gozde-Celik D, Gungordu Z et al. Hepatit Delta virüsü infeksiyonu seroprevalansi{dotless}:Retrospektif temelli seroepidemiyolojik bir deǧerlendirme [Seroprevalence of hepatitis delta virus infection: retrospective-based seroepidemiologic assessment]. Flora Derg 2011; 16: 120-126.
130. Bahcecioglu IH, Aygun C, Gozel N, Poyrazoglu OK, Bulut Y, Yalniz M. Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients in eastern Turkey: still a serious problem to consider. J Viral Hepat 2011; 18: 518-524.
131. Celik I, Karatayli E, Cevik E et al. Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. Arch Virol 2011; 156: 2215-2220.
132. Le Gal F, Badur S, Hawajri NA et al. Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV-1 origins. Arch Virol 2012; 157: 647-659.
133. Coskun O, Erdem H, Besirbellioglu BA, Eyigun CP. Distribution of hepatitis C virus infection in the male Turkish population. Int J Infect Dis 2006; 10: 481.
134. Keskin F, Ciftci S, Turkoglu S, Badur S. Transmission routes of chronic hepatitis C and their relation to HCV genotypes. Turk J Gastroenterol 2010; 21: 396-400.
135. Aktas E, Ogedey ED, Kulah C, Begendik Comert F. Hepatitis C virus genotypes in a province of western Black-Sea region, Turkey. Mikrobiyol Bul 2010; 44: 647-650.
136. Kuckoztas MF, Ozgunes N, Yazici S. Investigation of the relationship between hepatitis C virus (HCV) genotypes with HCV-RNA and alanine aminotransferase levels in chronic hepatitis C patients. Mikrobiyol Bul 2010; 44: 111-115.
137. Karahocagil MK, Baran AI, Yaman G et al. Case report: two Plasmodium vivax malaria cases in the Van province. Turkiye Parazitol Derg 2009; 33: 172-173.
138. Ozbilgin A, Topluoglu S, Es S, Islek E, Mollahaliloglu S, Erkoc Y. Malaria in Turkey: successful control and strategies for achieving elimination. Acta Trop 2011; 120: 15-23.
139. Erdem H, Pahsa A. Antibiotic resistance in pathogenic Streptococcus pneumoniae isolates in Turkey. J Chemother 2005; 17: 25-30.
140. Ozgenc O, Genc VE, Ari AA et al. Evaluation of the therapeutic use of antibiotics in Aegean region hospitals of Turkey: a multicentric study. Indian J Med Microbiol 2011; 29: 124-129.
141. Erdem H, Kurtaran B, Arun O et al. The place and the efficacy of infectious disease consultations in the hospitals. Infect Dis Clin Pract 2012; 20: 131-136.
142. Arda B, Sipahi OR, Yamazhan T et al. Short-term effect of antibiotic control policy on the usage patterns and cost of antimicrobials, mortality, nosocomial infection rates and antibacterial resistance. J Infect 2007; 55: 41-48.
143. Kurt H, Karabay O, Birengel S, Memikoglu O, Yilmaz Bozkurt G, Yalci A. Effects of legal antibiotic restrictions on consumption of broad-spectrum beta-lactam antibiotics, glycopeptides and amphotericin B. Chemotherapy 2010; 56: 359-363.
144. Oner A, Demircin G, Bulbul M. Post-streptococcal acute glomerulonephritis in Turkey. Acta Paediatr 1995; 84: 817-819.
145. Orun UA, Ceylan O, Bilici M et al. Acute rheumatic fever in the central Anatolia region of Turkey: a 30-year experience in a single center. Eur J Pediatr 2012; 171: 361-368.
146. Karademir S, Demirceken F, Atalay S, Demircin G, Sipahi T, Tezic T. Acute rheumatic fever in children in the Ankara area in 1990-1992 and comparison with a previous study in 1980-1989. Acta Paediatr 1994; 83: 862-865.
147. Ozer S, Hallioglu O, Ozkutlu S, Celiker A, Alehan D, Karagoz T. Childhood acute rheumatic fever in Ankara, Turkey. Turk J Pediatr 2005; 47: 120-124.
148. Dundar D, Sayan M, Tamer GS. Macrolide and tetracycline resistance and emm type distribution of Streptococcus pyogenes isolates recovered from Turkish patients. Microb Drug Resist 2010; 16: 279-284.
149. Bayramoglu G, Topkaya AE, Balikci A, Aydin F. Serotypes and antimicrobial susceptibilities of invasive group A streptococci identified in eastern Black Sea region of Turkey. Mikrobiyol Bul 2011; 45: 446-453.
150. Erdem H, Sener B. Pneumococcal seroepidemiology in Turkey: implications for vaccine coverage. Vaccine 2008; 26: 1271-1273.
151. Erdem H. An update on invasive pneumococcal antibiotic resistance in Turkey, 2008. J Chemother 2008; 20: 697-701.
152. Telli M, Eyigör M, Gültekin B, Aydin N. Streptococcus pneumoniae'nin menenjit disi klinik izolatlarinda penisilin direnci ile serotip iliskisi ve bazi{dotless} antibiyotiklere direnc [Penicillin resistance and serotype relationship in Streptococcus pneumoniae clinical isolates and resistance to some antibiotics]. Ankem Derg 2010; 24: 55-60.
153. Dogan O, Gulmez D, Hascelik G. Effect of new breakpoints proposed by clinical and laboratory standards institute in 2008 for evaluating penicillin resistance of Streptococcus pneumoniae in a Turkish university hospital. Microb Drug Resist 2010; 16: 39-41.
154. Pehlivanoǧlu F, Kart-Yaşar K, Şengöz G. Beyin omurilik si{dotless}vi{dotless}si{dotless}ndan izole edilen mikroorganizmalar ve antibiyotik duyarli{dotless}li{dotless}klari{dotless} [Microorganisms isolated from cerebrospinal fluid and their antibiotic resistance]. Ankem Derg 2011; 25: 1-5.
155. Ulug M, Ayaz C, Celen MK. A case report and literature review: osteomyelitis caused by community-associated methicillin resistant Staphylococcus aureus. J Infect Dev Ctries 2011; 5: 896-900.
156. Kara A, Tezer H, Devrim I et al. Primary sternal osteomyelitis in a healthy child due to community-acquired methicillin-resistant Staphylococcus aureus and literature review. Scand J Infect Dis 2007; 39: 469-472.
157. Ilki A, Sagiroglu P, Elgormus N, Soyletir G. Trends in antibiotic susceptibility patterns of Streptococcus pneumoniae and Haemophilus influenzae isolates: four years follow up. Mikrobiyol Bul 2010; 44: 169-175.
158. Gonullu N, Catal F, Kucukbasmaci O, Ozdemir S, Torun MM, Berkiten R. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey. Chemotherapy 2009; 55: 161-167.
159. Torun MM, Namal N, Demirci M, Bahar H. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis in healthy school children in Turkey. Indian J Med Microbiol 2009; 27: 86-88.
160. Uncu H, Colakoglu S, Turunc T, Demiroglu YZ, Arslan H. In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy. Mikrobiyol Bul 2007; 41: 441-446.
161. Sener B, Tunckanat F, Ulusoy S et al. A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004-2005. J Antimicrob Chemother 2007; 60: 587-593.
162. Torun MM, Namal N, Demirci M, Bahar H, Kocazeybek B. Pharyngeal carriage and antimicrobial resistance of Haemophilus influenzae in non-type-B-vaccinated healthy children attending day care centers in Turkey. Chemotherapy 2007; 53: 114-117.
163. Altun B, Gur D. Hacettepe Üniversitesi Çocuk Hastanesi'nde klinik örneklerden izole edilen Haemophilus influenzae suşlari{dotless}ni{dotless}n antibiyotiklere direnç durumu (2002-2007) [Antimicrobial resistance in Haemophilus influenzae strains isolated from various clinical samples in Hacettepe University Children's Hospital (2002-2007)]. Cocuk Enf Derg 2008; 2: 50-54.
164. Özkul H, Alpay-Özbek Ö, Çoban H, Gülay Z. Dokuz Eylül Üniversitesi Hastanesinde 2003-2006 yillarinda uretilen Haemophilus influenzae suslarinin antibiyotik duyarliliklari. Ankem Derg 2007; 21: 86-90.
165. Coskun O, Erdem H, Avci A. Management of community-acquired acute bacterial cystitis in Turkey. Turk J Med Sci 2011; 41: 149-157.
166. Ceran N, Mert D, Kocdogan FY et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother 2010; 16: 424-430.
167. Aypak C, Altunsoy A, Duzgun N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob 2009; 8: 27.
168. Guneysel O, Onur O, Erdede M, Denizbasi A. Trimethoprim/sulfamethoxazole resistance in urinary tract infections. J Emerg Med 2009; 36: 338-341.
169. Arslan H, Azap ÖK, Ergönül Ö, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56: 914-918.
170. Karaca Y, Coplu N, Gozalan A, Oncul O, Citil BE, Esen B. Co-trimoxazole and quinolone resistance in Escherichia coli isolated from urinary tract infections over the last 10 years. Int J Antimicrob Agents 2005; 26: 75-77.
171. Azap OK, Arslan H, Serefhanoglu K et al. Risk factors for extended-spectrum β-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010; 16: 147-151.
172. Celik AD, Yulugkural Z, Kuloglu F et al. CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey. J Microbiol Immunol Infect 2010; 43: 163-167.
173. Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP. Turkey: a further country concerned by community-acquired Escherichia coli clone o25-st131 producing CTX-M-15. J Antimicrob Chemother 2008; 62: 284-288.
174. Bahar G, Mert A, Catania MR, Koncan R, Benvenuti C, Mazzariol A. A strain of Salmonella enterica serovar virchow isolated in Turkey and carrying a CTX-M-3 extended-spectrum beta-lactamase. J Chemother 2006; 18: 307-310.
175. Budak F, Nordmann P, Girlich D, Gur D. Characterization of extended-spectrum beta-lactamase-producing Salmonella isolates in a children's hospital in Ankara-first report of SHV-2a and SHV-9 in Salmonella spp. from Turkey. Turk J Pediatr 2009; 51: 28-34.
176. Kilic D, Tulek N, Tuncer G, Doganci L, Willke A. Antimicrobial susceptibilities and ESBL production rates of Salmonella and Shigella strains in Turkey. Clin Microbiol Infect 2001; 7: 341-342.
177. Otkun M, Erdem B, Akata F et al. Antibiotic resistance patterns and plasmid profiles of Salmonella typhimurium isolates in Turkey. Eur J Clin Microbiol Infect Dis 2001; 20: 206-209.
178. Ercis S, Erdem B, Hascelik G, Gur D. Nalidixic acid resistance in Salmonella strains with decreased susceptibility to ciprofloxacin isolated from humans in Turkey. Jpn J Infect Dis 2006; 59: 117-119.
179. Yalcin AN, Hayran M, Unal S. Economic analysis of nosocomial infections in a Turkish university hospital. J Chemother 1997; 9: 411-414.
180. Khan MM, Celik Y. Cost of nosocomial infection in Turkey: an estimate based on the university hospital data. Health Serv Manage Res 2001; 14: 49-54.
181. Inan D, Saba R, Gunseren F et al. Daily antibiotic cost of nosocomial infections in a Turkish university hospital. BMC Infect Dis 2005; 5: 5.
182. Inan A, Dagli O, Şenbayrak-Akçay S, Öztürk-Engin D, Karagül E, Çelik-Özyürek S. Antibiotic use and cost in a teaching hospital in Istanbul. J Microbiol Infect Dis 2011; 1: 128-133.
183. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56: 519-523.
184. Kuscu F, Ozturk DB, Gurbuz Y, Tutuncu EE, Sencan I, Gul S. Investigation of reduced vancomycin susceptibility in methicillin-resistant staphylococci. Mikrobiyol Bul 2011; 45: 248-257.
185. Aktas E, Mengeloglu FZ, Kulah C, Comert FB. Evaluation of reduced susceptibility to vancomycin among MRSA strains isolated from clinical specimens. Mikrobiyol Bul 2010; 44: 339-341.
186. Vural T, Sekercioglu AO, Ogunc D et al. Vankomisine dirençli Enterococcus faecium suşu [Vancomycin-resistant Enterococcus faecium strain]. Ankem Derg 1999; 13: 1-4.
187. Erdem H, Oncul O. A review of the current place of glycopeptides in Turkish medical practice. Curr Ther Res Clin Exp 2007; 68: 49-66.
188. Yucel N, Citak S, Bayhun S. Antimicrobial resistance profile of Staphylococcus aureus isolated from clinical samples and foods of animal origin. Foodborne Pathog Dis 2011; 8: 427-431.
189. Efe S, Sinirtas M, Ozakin C. In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus strains. Mikrobiyol Bul 2009; 43: 639-643.
190. Tunger A, Aydemir S, Uluer S, Cilli F. In vitro activity of linezolid & quinupristin/dalfopristin against gram-positive cocci. Indian J Med Res 2004; 120: 546-552.
191. Pelitli TS, Cesur S, Kinikli S, Irmak H, Demiroz AP, Karakoc E. Evaluation of vancomycin, teicoplanin, linezolide and tigecycline susceptibilities of nosocomial methicillin-resistant Staphylococcus strains by e-test. Mikrobiyol Bul 2011; 45: 758-761.
192. Eser OK, Ergin A, Tunckanat F, Hascelik G. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp. New Microbiol 2008; 31: 535-542.
193. Bayramoglu G, Kaya S, Besli Y et al. Molecular epidemiology and the clinical significance of Acinetobacter baumannii complex isolated from cerebrospinal fluid in neurosurgical intensive care unit patients. Infection 2011; 40: 163-172.
194. Eraksoy H, Basustaoglu A, Korten V et al. Susceptibility of bacterial isolates from Turkey-a report from the meropenem yearly susceptibility test information collection (MYSTIC) program. J Chemother 2007; 19: 650-657.
195. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant gram-negative bacilli in Europe. Euro Surveill 2008; 13: 19045.
196. Gur D, Hascelik G, Aydin N et al. Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 surveillance study of 2007. J Chemother 2009; 21: 383-389.
197. Vahaboglu H, Coskunkan F, Tansel O et al. Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microbiol 2001; 50: 642-645.
198. Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H. PER-1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett 2005; 249: 241-245.
199. Vahaboglu H, Ozturk R, Aygun G et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41: 2265-2269.
200. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
201. Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18: 413-431.
202. Carrer A, Poirel L, Yilmaz M et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother 2010; 54: 1369-1373.
203. Levast M, Poirel L, Carrer A et al. Transfer of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae from Turkey to France. J Antimicrob Chemother 2011; 66: 944-945.
204. Meric M, Kasap M, Gacar G et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Turkey. FEMS Microbiol Lett 2008; 282: 214-218.
205. Vahaboglu H, Budak F, Kasap M et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58: 537-542.
206. Poirel L, Ozdamar M, Ocampo-Sosa AA, Turkoglu S, Ozer UG, Nordmann P. NDM-1-producing Klebsiella pneumoniae now in Turkey. Antimicrob Agents Chemother 2012; 56: 2784-2785.